JP2006501165A5 - - Google Patents

Download PDF

Info

Publication number
JP2006501165A5
JP2006501165A5 JP2004510817A JP2004510817A JP2006501165A5 JP 2006501165 A5 JP2006501165 A5 JP 2006501165A5 JP 2004510817 A JP2004510817 A JP 2004510817A JP 2004510817 A JP2004510817 A JP 2004510817A JP 2006501165 A5 JP2006501165 A5 JP 2006501165A5
Authority
JP
Japan
Prior art keywords
peptide
composition
subject
exposed
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004510817A
Other languages
English (en)
Japanese (ja)
Other versions
JP4460445B2 (ja
JP2006501165A (ja
Filing date
Publication date
Priority claimed from US10/165,250 external-priority patent/US20030108539A1/en
Application filed filed Critical
Publication of JP2006501165A publication Critical patent/JP2006501165A/ja
Publication of JP2006501165A5 publication Critical patent/JP2006501165A5/ja
Application granted granted Critical
Publication of JP4460445B2 publication Critical patent/JP4460445B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2004510817A 2002-06-07 2003-06-09 Ｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤 Expired - Lifetime JP4460445B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/165,250 US20030108539A1 (en) 2000-02-14 2002-06-07 Cell-permeable peptide inhibitors of the JNK signal transduction pathway
PCT/IB2003/003094 WO2003103698A1 (en) 2002-06-07 2003-06-09 Cell-permeable peptide inhibitors of the jnk signal transduction pathway

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009272904A Division JP2010053136A (ja) 2002-06-07 2009-11-30 Ｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤

Publications (3)

Publication Number Publication Date
JP2006501165A JP2006501165A (ja) 2006-01-12
JP2006501165A5 true JP2006501165A5 (https=) 2010-02-18
JP4460445B2 JP4460445B2 (ja) 2010-05-12

Family

ID=29732060

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004510817A Expired - Lifetime JP4460445B2 (ja) 2002-06-07 2003-06-09 Ｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤
JP2009272904A Withdrawn JP2010053136A (ja) 2002-06-07 2009-11-30 Ｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009272904A Withdrawn JP2010053136A (ja) 2002-06-07 2009-11-30 Ｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤

Country Status (14)

Country Link
US (1) US20030108539A1 (https=)
EP (7) EP1511507B1 (https=)
JP (2) JP4460445B2 (https=)
AT (2) ATE417623T1 (https=)
AU (1) AU2003274820B2 (https=)
CA (1) CA2488695C (https=)
CY (3) CY1108847T1 (https=)
DE (2) DE60325429D1 (https=)
DK (2) DK1911458T5 (https=)
ES (3) ES2473274T3 (https=)
HK (1) HK1207971A1 (https=)
PT (3) PT1911458E (https=)
SI (1) SI1776958T1 (https=)
WO (1) WO2003103698A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en) * 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
EP1656951A1 (en) * 2004-11-12 2006-05-17 Xigen S.A. Conjugates with enhanced cell uptake activity
EP1661912A1 (en) * 2004-11-29 2006-05-31 Xigen S.A. Fusion protein comprising a BH3-domain of a BH3-only protein
US20060223807A1 (en) 2005-03-29 2006-10-05 University Of Massachusetts Medical School, A Massachusetts Corporation Therapeutic methods for type I diabetes
US8080517B2 (en) * 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) * 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
CA2663545A1 (en) 2006-09-19 2008-03-27 Phylogica Limited Neuroprotective peptide inhibitors of ap-1 signaling and uses thereof
CA2989778C (en) 2007-01-19 2020-06-30 Kai Pharmaceuticals, Inc. Method of modifying peptide compositions
US8822409B2 (en) 2007-06-20 2014-09-02 Phylogica Limited Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ARDS) and clinical disorders associated with therewith
WO2009143865A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
WO2010113753A1 (ja) * 2009-03-30 2010-10-07 参天製薬株式会社 ＪＮＫ（ｃ－Ｊｕｎアミノ末端キナーゼ）阻害ペプチドを用いた網膜疾患の予防または治療剤、網膜疾患の予防または治療方法、ならびに、その使用
JP5457813B2 (ja) * 2009-12-16 2014-04-02 ルネサスエレクトロニクス株式会社 Ａｄｐｌｌ回路、半導体装置及び携帯情報機器
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
WO2012048721A1 (en) 2010-10-14 2012-04-19 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2012112810A1 (en) * 2011-02-18 2012-08-23 Otonomy, Inc. Prevention of and recovery from drug-induced ototoxicity
JP2015500213A (ja) * 2011-11-30 2015-01-05 ザイジェン インフラメーション リミテッド 眼乾燥症候群を処置するためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の使用
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2014206426A1 (en) * 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
KR20160023669A (ko) 2013-06-26 2016-03-03 자이겐 인플라메이션 리미티드 다양한 질병의 치료를 위한 jnk 신호 전달 경로의 세포 투과성 펩타이드 억제자의 새로운 용도
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
GB201719520D0 (en) * 2017-11-24 2018-01-10 Univ College Cardiff Consultants Ltd Neuroprotectvie peptide
CN109182250A (zh) * 2018-09-30 2019-01-11 山东省立医院 一种小鼠耳蜗毛细胞培养方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US817457A (en) * 1906-01-18 1906-04-10 Kelley M Turner Head band or support for telephone-receivers.
US1447969A (en) * 1922-05-12 1923-03-13 Brandes Inc C Telephone head set
US4048453A (en) * 1976-02-11 1977-09-13 Gustave Seidel Telephone handset support device
US4631211A (en) * 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
DE4005783A1 (de) * 1990-02-23 1991-09-05 Andreas Suckert Kopfhalterung fuer telefonhoerer
ES2123062T3 (es) * 1992-08-21 1999-01-01 Biogen Inc Polipeptidos de transporte derivados de la proteina tat.
ES2157225T3 (es) 1992-10-09 2001-08-16 Advanced Tissue Sciences Inc Celulas hepaticas de reserva.
WO1996034093A1 (en) * 1995-04-25 1996-10-31 Baxter International Inc. Composition containing collagenase and chymopapain for isolating hepatocytes and pancreatic islet cells
ATE365808T1 (de) 1995-07-28 2007-07-15 Marie Curie Cancer Care Transportproteine und deren verwendungen
US5689558A (en) * 1996-03-25 1997-11-18 Osgood; Alan G. Telephone handset holder
US5880261A (en) * 1997-04-03 1999-03-09 Waeber; Gerard Transcription factor Islet-Brain 1 (IB1)
US5828749A (en) * 1997-04-04 1998-10-27 Brodskiy; Arkadiy Phone holder kit
US6043083A (en) * 1997-04-28 2000-03-28 Davis; Roger J. Inhibitors of the JNK signal transduction pathway and methods of use
EP0897002A3 (en) * 1997-08-14 2001-10-04 Smithkline Beecham Plc U62317, a protein having a JNK-binding domain
EP0947524A1 (en) * 1998-03-30 1999-10-06 Upither B.V. Novel peptides for the treatment of autoimmune diseases
AU3714499A (en) * 1998-05-14 1999-11-29 Pasteur Merieux Serums Et Vaccins Hepatitis c virus mimotopes
CA2328457A1 (en) * 1998-06-20 1999-12-29 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
EP1126855B1 (en) * 1998-09-25 2007-05-09 Cephalon, Inc. Use of fused pyrrolocarbazoles for preventing/treating damage to sensory hair cells and cochlear neurons
US6610820B1 (en) * 1999-10-12 2003-08-26 University Of Lausanne Cell-permeable peptide inhibitors of the JNK signal transduction pathway
CA2392615A1 (en) * 1999-12-06 2001-06-07 The General Hospital Corporation Pancreatic stem cells and their use in transplantation
EP1333846B1 (en) * 2000-10-17 2012-04-18 Diabcell Pty Limited Preparation and xenotransplantation or porcine islets
DE10117281A1 (de) * 2001-04-06 2002-10-24 Inst Molekulare Biotechnologie Peptid zur Diagnose und Therapie der Alzheimer-Demenz
EP1373308B1 (en) * 2001-04-06 2006-10-25 Thomas Jefferson University Antagonist for multimerization of hiv-1 vif protein

Similar Documents

Publication Publication Date Title
JP2006501165A5 (https=)
ES2732252T3 (es) Procedimientos para tratar diabetes y/o promover la supervivencia de los islotes pancreáticos después del trasplante
CZ20014289A3 (cs) Nové pouľití sloučenin jako antibakteriálních činidel
NZ527157A (en) Compositions for delivering bisphosphonates
Barbounis et al. Control of irinotecan-induced diarrhea by octreotide after loperamide failure
CA2332817A1 (en) Il-6 antagonist peptides
CA2488695A1 (en) Cell-permeable peptide inhibitors of the jnk signal transduction pathway
CA2442909A1 (en) Multimerization of hiv-1 vif protein as a therapeutic target
WO2010107476A1 (en) Inhibiting gsnor
WO2011149964A3 (en) Methods for treating or preventing vascular graft failure
SE9800550D0 (sv) A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
HUP9901586A2 (hu) Antifungális szert és acetátpuffert tartalmazó készítmények és alkalmazásuk
JP2021509916A5 (https=)
JP2011517675A5 (https=)
JP2011506436A (ja) 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
RU2016110153A (ru) Новые пептиды и их аналоги для применения при лечении мукозита полости рта
ATE383850T1 (de) Pulver enthaltend neuartige oligosaccharidgemische und verfahren zu deren herstellung
JP2021500409A5 (https=)
JP2009530359A (ja) 腫瘍成長の阻害
JP2025027020A (ja) 患者において血清リン酸塩を低下させるための組み合わせ
CN100418532C (zh) 治疗多种疾病的NF-κB化合物抑制剂
KR20080099234A (ko) 콤브레타스타틴 및 항암제를 포함하는 조합물
JP2019108277A5 (https=)
AU5158000A (en) Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
CA2493859A1 (en) Preventive/remedy for arteriosclerosis comprising adiponectin